Lexicon Completes SONATA-HCM Enrollment; Sotagliflozin HCM Data Expected in 2027

What happened

Lexicon Pharmaceuticals announced completion of enrollment in the Phase III SONATA-HCM study of sotagliflozin for hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027. This operational milestone signals steady execution of a key pipeline program, but the readout remains roughly two years away, offering no near-term catalyst. The company continues its strategic pivot toward cardiometabolic opportunities, yet near-term fundamentals still depend heavily on partnership milestones and modest U.S. INPEFA sales, which have shown limited traction. Enrollment completion does not de-risk the clinical outcome or alter the competitive landscape dominated by established SGLT2 inhibitors. Overall, the news is a minor positive but does not change the investment thesis at this time.

Implication

Investors should view completed enrollment as operational progress but not a value inflection. The company remains reliant on non-dilutive partnership cash (Viatris, Novo) and disciplined spending to weather the wait until 2027. Key nearer-term catalysts, such as LX9211 Phase 3 initiation and LX9851 advancement under Novo, are more likely to move the needle. Maintain HOLD with a focus on cash runway and pipeline execution.

Thesis delta

No change to HOLD thesis. The completion of SONATA-HCM enrollment is an incremental positive that confirms execution but does not alter near-term value drivers. The outlook remains neutral until clinical data or partnership milestones provide clearer catalysts.